Alejandra Rios-Sanchez

S.A. De C.V
Zapopan, JAL, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease.

Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: July 23, 2024

The Effect of Sodium Hyaluronate Eye Drops 2, 4 or 6 Times a Day on Signs and Symptoms of Dry Eye Disease.

The Effect of Sodium Hyaluronate Eye Drops 2, 4 or 6 Times a Day on Signs and Symptoms of Dry Eye Disease.

Journal: Clinical ophthalmology (Auckland, N.Z.)

Published: August 03, 2023

Evaluation of the Relationship Between Diabetic Macular Edema and Renal Function in a Latino Population.

Evaluation of the Relationship Between Diabetic Macular Edema and Renal Function in a Latino Population.

Journal: Ophthalmology and therapy

Published: July 11, 2023

Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial.

Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial.

Journal: Journal of ophthalmology

Published: June 24, 2022

Evaluation of the Rheological Properties, Preclinical Safety, and Clinical Effectiveness of a New Dispersive Ophthalmic Viscoelastic Device for Cataract Surgery.

Evaluation of the Rheological Properties, Preclinical Safety, and Clinical Effectiveness of a New Dispersive Ophthalmic Viscoelastic Device for Cataract Surgery.

Journal: Medical devices (Auckland, N.Z.)

Published: June 18, 2022

Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate.

Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate.

Journal: Animal models and experimental medicine

Published: September 21, 2021

Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials.

Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials.

Journal: Therapeutics and clinical risk management

Published: July 29, 2021

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab.

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab.

Journal: Journal of experimental pharmacology

Published: February 27, 2021

Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits.

Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits.

Journal: International journal of retina and vitreous

Published: November 27, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026